Dual Antiplatelet Therapy in Coronary Artery Disease

go back to reference Chan MY, Du X, Eccleston D, et al. Acute coronary syndrome in the Asia-Pacific region. Int J Cardiol. 2016;1(202):861–9.CrossRef Chan MY, Du X, Eccleston D, et al. Acute coronary syndrome in the Asia-Pacific region. Int J Cardiol. 2016;1(202):861–9.CrossRef

go back to reference Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014;114(12):1959–75. https://doi.org/10.1161/CIRCRESAHA.114.302782.CrossRefPubMedPubMedCentral Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014;114(12):1959–75. https://​doi.​org/​10.​1161/​CIRCRESAHA.​114.​302782.CrossRefPubMedPubMedCentral

go back to reference Ohira T, Iso H. Cardiovascular disease epidemiology in Asia. Circ J. 2013;77(7):1646–52.CrossRefPubMed Ohira T, Iso H. Cardiovascular disease epidemiology in Asia. Circ J. 2013;77(7):1646–52.CrossRefPubMed

go back to reference Wilson SJ, Newby DE, Dawson D, et al. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–80.CrossRefPubMed Wilson SJ, Newby DE, Dawson D, et al. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–80.CrossRefPubMed

go back to reference Degrauwe S, Pilgrim T, Aminian A, et al. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2):e000651.CrossRefPubMedPubMedCentral Degrauwe S, Pilgrim T, Aminian A, et al. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2):e000651.CrossRefPubMedPubMedCentral

go back to reference PLAVIX® (clopidogrel bisulfate) tablets [package insert on the Internet]. Bridgewater, (NJ): Sanofi-Aventis. 1997. https://packageinserts.bms.com/pi/pi_plavix.pdf. Accessed 11 Sep 2018. PLAVIX® (clopidogrel bisulfate) tablets [package insert on the Internet]. Bridgewater, (NJ): Sanofi-Aventis. 1997. https://​packageinserts.​bms.​com/​pi/​pi_​plavix.​pdf. Accessed 11 Sep 2018.

go back to reference Effient® (prasugrel) tablets [package insert on the Internet]. Indianapolis (IN): Eli Lilly. 2009. https://pi.lilly.com/us/effient.pdf. Accessed 11 Sep 2018. Effient® (prasugrel) tablets [package insert on the Internet]. Indianapolis (IN): Eli Lilly. 2009. https://​pi.​lilly.​com/​us/​effient.​pdf. Accessed 11 Sep 2018.

go back to reference BRILINTA® (ticagrelor) tablets [package insert on the Internet]. Wilmington (DE): AstraZeneca Pharmaceuticals. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf. Accessed 11 Sep 2018. BRILINTA® (ticagrelor) tablets [package insert on the Internet]. Wilmington (DE): AstraZeneca Pharmaceuticals. 2011. https://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2016/​022433s020lbl.​pdf. Accessed 11 Sep 2018.

go back to reference Biasco L, Montrasio G, Moccetti M, Pedrazzini G. Current trends in dual antiplatelet therapy: a 2017 update. Cardiovasc Med. 2017;20(7–8):169–75. Biasco L, Montrasio G, Moccetti M, Pedrazzini G. Current trends in dual antiplatelet therapy: a 2017 update. Cardiovasc Med. 2017;20(7–8):169–75.

go back to reference Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–155.CrossRefPubMed Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–155.CrossRefPubMed

go back to reference Wiviott SD, White HD, Ohman EM, Fox KA, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013;382:605–13.CrossRefPubMed Wiviott SD, White HD, Ohman EM, Fox KA, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet. 2013;382:605–13.CrossRefPubMed

go back to reference Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.CrossRefPubMed Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.CrossRefPubMed

go back to reference Pareek M, Bhatt D. Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. Eur Heart J Suppl. 2018;20(suppl B):B21–B2828.CrossRef Pareek M, Bhatt D. Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond. Eur Heart J Suppl. 2018;20(suppl B):B21–B2828.CrossRef

go back to reference Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114,364 survivors of myocardial infarction. Eur Heart J. 2016;2(3):172–83. Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114,364 survivors of myocardial infarction. Eur Heart J. 2016;2(3):172–83.

go back to reference Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Am J Ophthalmol. 2006;142(2):366.CrossRef Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Am J Ophthalmol. 2006;142(2):366.CrossRef

go back to reference Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.CrossRefPubMed Bonaca MP, Bhatt DL, Cohen M, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.CrossRefPubMed

go back to reference Mauri L, Kereiakes DJ, Yeh RW, DAPT Study Investigators, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66.CrossRefPubMedPubMedCentral Mauri L, Kereiakes DJ, Yeh RW, DAPT Study Investigators, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66.CrossRefPubMedPubMedCentral

go back to reference Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–27. https://doi.org/10.1001/jama.2019.8145.CrossRefPubMedPubMedCentral Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–27. https://​doi.​org/​10.​1001/​jama.​2019.​8145.CrossRefPubMedPubMedCentral

go back to reference Hahn J, Song YB, Oh J, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–37. https://doi.org/10.1001/jama.2019.8146.CrossRefPubMedPubMedCentral Hahn J, Song YB, Oh J, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–37. https://​doi.​org/​10.​1001/​jama.​2019.​8146.CrossRefPubMedPubMedCentral

go back to reference Vranckx P, Valgimigli M, Jüni P, GLOBAL LEADERS Investigators, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018. https://doi.org/10.1016/S0140-6736(18)31858-0.CrossRefPubMed Vranckx P, Valgimigli M, Jüni P, GLOBAL LEADERS Investigators, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018. https://​doi.​org/​10.​1016/​S0140-6736(18)31858-0.CrossRefPubMed

go back to reference Mehran R, Baber U, Sharma S, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–42.CrossRefPubMed Mehran R, Baber U, Sharma S, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–42.CrossRefPubMed

go back to reference Kim B, Hong S, Cho Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–16. https://doi.org/10.1001/jama.2020.7580.CrossRefPubMedPubMedCentral Kim B, Hong S, Cho Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–16. https://​doi.​org/​10.​1001/​jama.​2020.​7580.CrossRefPubMedPubMedCentral

go back to reference Steg P, Bhatt D, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309–20.CrossRefPubMed Steg P, Bhatt D, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309–20.CrossRefPubMed

go back to reference Bhatt D, Steg P, Mehta S, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Clin Trial. 2019. https://doi.org/10.1016/S0140-6736(19)31887-2.CrossRef Bhatt D, Steg P, Mehta S, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Clin Trial. 2019. https://​doi.​org/​10.​1016/​S0140-6736(19)31887-2.CrossRef

go back to reference Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Circulation. 2016;134(21):1603–12.CrossRefPubMed Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Circulation. 2016;134(21):1603–12.CrossRefPubMed

go back to reference Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.CrossRefPubMed Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.CrossRefPubMed

go back to reference Zhao X, Li J, Tang X, et al. Prognostic value of the PARIS thrombotic risk score for 2-year mortality after percutaneous coronary intervention. Clin Appl Thromb Hemost. 2019;25:1076029619853638. https://doi.org/10.1177/1076029619853638.CrossRefPubMedPubMedCentral Zhao X, Li J, Tang X, et al. Prognostic value of the PARIS thrombotic risk score for 2-year mortality after percutaneous coronary intervention. Clin Appl Thromb Hemost. 2019;25:1076029619853638. https://​doi.​org/​10.​1177/​1076029619853638​.CrossRefPubMedPubMedCentral

go back to reference Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–61. https://doi.org/10.1161/CIRCULATIONAHA.119.040167.CrossRefPubMedPubMedCentral Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–61. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​119.​040167.CrossRefPubMedPubMedCentral

go back to reference Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981–9.CrossRefPubMed Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981–9.CrossRefPubMed

go back to reference Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394.CrossRefPubMed Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://​doi.​org/​10.​1093/​eurheartj/​ehy394.CrossRefPubMed

go back to reference Yasuda H, Yamada M, Sawada S, Endo Y, Inoue K, Asano F, Takeyama Y, Yoshiba M. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med. 2009;48:1725–30.CrossRefPubMed Yasuda H, Yamada M, Sawada S, Endo Y, Inoue K, Asano F, Takeyama Y, Yoshiba M. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med. 2009;48:1725–30.CrossRefPubMed

go back to reference Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol. 2007;102:2411–6.CrossRefPubMed Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol. 2007;102:2411–6.CrossRefPubMed

go back to reference Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.CrossRefPubMed Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.CrossRefPubMed

go back to reference Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54:1293–302.CrossRefPubMed Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54:1293–302.CrossRefPubMed

go back to reference Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.CrossRefPubMed Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.CrossRefPubMed

go back to reference Yasuda H, Matsuo Y, Sato Y, et al. Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med. 2015;4(1):40–6. https://doi.org/10.5492/wjccm.v4.i1.40.CrossRefPubMedPubMedCentral Yasuda H, Matsuo Y, Sato Y, et al. Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med. 2015;4(1):40–6. https://​doi.​org/​10.​5492/​wjccm.​v4.​i1.​40.CrossRefPubMedPubMedCentral

go back to reference Levine GN, Jeong YH, Goto S, et al. World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Glob Heart. 2014;9(4):457–67. https://doi.org/10.1016/j.gheart.2014.08.001.CrossRefPubMed Levine GN, Jeong YH, Goto S, et al. World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Glob Heart. 2014;9(4):457–67. https://​doi.​org/​10.​1016/​j.​gheart.​2014.​08.​001.CrossRefPubMed

go back to reference Floyd CN. Dual antiplatelet therapy in coronary artery disease: comparison between ACC/AHA 2016 and ESC 2017 guidelines. Eur Cardiol. 2020;15:1–3. https://doi.org/10.15420/ecr.2019.09.CrossRefPubMed Floyd CN. Dual antiplatelet therapy in coronary artery disease: comparison between ACC/AHA 2016 and ESC 2017 guidelines. Eur Cardiol. 2020;15:1–3. https://​doi.​org/​10.​15420/​ecr.​2019.​09.CrossRefPubMed

go back to reference Asia-Pacific ACS Medical Management Working Group, Huo Y, Thompson P, et al. Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. Int J Cardiol. 2015;183:63–75. https://doi.org/10.1016/j.ijcard.2014.11.195.CrossRef Asia-Pacific ACS Medical Management Working Group, Huo Y, Thompson P, et al. Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. Int J Cardiol. 2015;183:63–75. https://​doi.​org/​10.​1016/​j.​ijcard.​2014.​11.​195.CrossRef

go back to reference Levine GN, Bates ER, Bittl JA, Brindis RG, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable Ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–e155155.PubMed Levine GN, Bates ER, Bittl JA, Brindis RG, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable Ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–e155155.PubMed

go back to reference Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60.CrossRefPubMed Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60.CrossRefPubMed